5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
LABA O
increase O
the O
risk O
of O
asthma-related O
death O
. O

( O
5.1 O
) O
* O
Do O
not O
initiate O
in O
acutely O
deteriorating O
COPD O
or O
to O
treat O
acute O
symptoms O
. O

( O
5.2 O
) O
* O
Do O
not O
use O
in O
combination O
with O
an O
additional O
medicine O
containing O
LABA O
because O
of O
risk O
of O
overdose O
. O

( O
5.3 O
) O
* O
If O
paradoxical O
bronchospasm O
occurs O
, O
discontinue O
ANORO O
ELLIPTA O
and O
institute O
alternative O
therapy O
. O

( O
5.5 O
) O
* O
Use O
with O
caution O
in O
patients O
with O
cardiovascular O
disorders O
( O
5.7 O
) O
* O
Use O
with O
caution O
in O
patients O
with O
convulsive O
disorders O
, O
thyrotoxicosis O
, O
diabetes O
mellitus O
, O
and O
ketoacidosis O
. O

( O
5.8 O
) O
* O
Worsening O
of O
narrow-angle O
glaucoma O
may O
occur O
. O

Use O
with O
caution O
in O
patients O
with O
narrow-angle O
glaucoma O
and O
instruct O
patients O
to O
contact O
a O
physician O
immediately O
if O
symptoms O
occur O
. O

( O
5.9 O
) O
* O
Worsening O
of O
urinary O
retention O
may O
occur O
. O

Use O
with O
caution O
in O
patients O
with O
prostatic O
hyperplasia O
or O
bladder-neck O
obstruction O
and O
instruct O
patients O
to O
contact O
a O
physician O
immediately O
if O
symptoms O
occur O
. O

( O
5.10 O
) O
* O
Be O
alert O
to O
hypokalemia O
and O
hyperglycemia O
. O

( O
5.11 O
) O
5.1 O
Asthma-Related O
Death O
* O
Data O
from O
a O
large O
placebo-controlled O
trial O
in O
subjects O
with O
asthma B-Not_AE_Candidate
showed O
that O
LABA O
may O
increase O
the O
risk O
of O
asthma B-NonOSE_AE
-related O
death B-NonOSE_AE
. O

Data O
are O
not O
available O
to O
determine O
whether O
the O
rate O
of O
death B-NonOSE_AE
in O
patients O
with O
COPD B-Not_AE_Candidate
is O
increased O
by O
LABA O
. O

* O
A O
28-week O
, O
placebo-controlled O
, O
US O
trial O
comparing O
the O
safety O
of O
another O
LABA O
( O
salmeterol O
) O
with O
placebo O
, O
each O
added O
to O
usual O
asthma O
therapy O
, O
showed O
an O
increase O
in O
asthma B-NonOSE_AE
-related O
deaths B-NonOSE_AE
in O
subjects O
receiving O
salmeterol O
( O
13/13,176 O
in O
subjects O
treated O
with O
salmeterol O
vs O
. O
3/13,179 O
in O
subjects O
treated O
with O
placebo O
; O
relative O
risk O
: O
4.37 O
[ O
95 O
% O
CI O
: O
1.25 O
, O
15.34 O
] O
) O
. O

The O
increased O
risk O
of O
asthma B-OSE_Labeled_AE
-related O
death B-NonOSE_AE
is O
considered O
a O
class O
effect O
of O
LABA O
, O
including O
vilanterol O
, O
one O
of O
the O
active O
ingredients O
in O
ANORO O
ELLIPTA O
. O

* O
No O
trial O
adequate O
to O
determine O
whether O
the O
rate O
of O
asthma B-NonOSE_AE
-related O
death B-NonOSE_AE
is O
increased O
in O
subjects O
treated O
with O
ANORO O
ELLIPTA O
has O
been O
conducted O
. O

The O
safety O
and O
efficacy O
of O
ANORO O
ELLIPTA O
in O
patients O
with O
asthma B-Not_AE_Candidate
have O
not O
been O
established O
. O

ANORO O
ELLIPTA O
is O
not O
indicated O
for O
the O
treatment O
of O
asthma B-Not_AE_Candidate
. O

5.2 O
Deterioration O
of O
Disease O
and O
Acute O
Episodes O
ANORO O
ELLIPTA O
should O
not O
be O
initiated O
in O
patients O
during O
rapidly O
deteriorating O
or O
potentially O
life-threatening O
episodes O
of O
COPD B-Not_AE_Candidate
. O

ANORO O
ELLIPTA O
has O
not O
been O
studied O
in O
subjects O
with O
acutely O
deteriorating O
COPD B-Not_AE_Candidate
. O

The O
initiation O
of O
ANORO O
ELLIPTA O
in O
this O
setting O
is O
not O
appropriate O
. O

ANORO O
ELLIPTA O
should O
not O
be O
used O
for O
the O
relief O
of O
acute O
symptoms O
, O
i.e. O
, O
as O
rescue O
therapy O
for O
the O
treatment O
of O
acute O
episodes O
of O
bronchospasm B-Not_AE_Candidate
. O

ANORO O
ELLIPTA O
has O
not O
been O
studied O
in O
the O
relief O
of O
acute O
symptoms O
and O
extra O
doses O
should O
not O
be O
used O
for O
that O
purpose O
. O

Acute O
symptoms O
should O
be O
treated O
with O
an O
inhaled O
, O
short-acting O
beta2-agonist O
. O

When O
beginning O
treatment O
with O
ANORO O
ELLIPTA O
, O
patients O
who O
have O
been O
taking O
oral O
or O
inhaled O
, O
short-acting O
beta2-agonists O
on O
a O
regular O
basis O
( O
e.g. O
, O
4 O
times O
a O
day O
) O
should O
be O
instructed O
to O
discontinue O
the O
regular O
use O
of O
these O
drugs O
and O
to O
use O
them O
only O
for O
symptomatic O
relief O
of O
acute B-NonOSE_AE
respiratory I-NonOSE_AE
symptoms I-NonOSE_AE
. O

When O
prescribing O
ANORO O
ELLIPTA O
, O
the O
healthcare O
provider O
should O
also O
prescribe O
an O
inhaled O
, O
short-acting O
beta2-agonist O
and O
instruct O
the O
patient O
on O
how O
it O
should O
be O
used O
. O

Increasing O
inhaled O
, O
short-acting O
beta2-agonist O
use O
is O
a O
signal O
of O
deteriorating O
disease O
for O
which O
prompt O
medical O
attention O
is O
indicated O
. O

COPD B-Not_AE_Candidate
may O
deteriorate O
acutely O
over O
a O
period O
of O
hours O
or O
chronically O
over O
several O
days O
or O
longer O
. O

If O
ANORO O
ELLIPTA O
no O
longer O
controls O
symptoms O
of O
bronchoconstriction B-NonOSE_AE
; O
the O
patient O
's O
inhaled O
, O
short-acting O
beta2-agonist O
becomes O
less O
effective O
; O
or O
the O
patient O
needs O
more O
short-acting O
beta2-agonist O
than O
usual O
, O
these O
may O
be O
markers O
of O
deterioration O
of O
disease O
. O

In O
this O
setting O
a O
re-evaluation O
of O
the O
patient O
and O
the O
COPD B-Not_AE_Candidate
treatment O
regimen O
should O
be O
undertaken O
at O
once O
. O

Increasing O
the O
daily O
dose O
of O
ANORO O
ELLIPTA O
beyond O
the O
recommended O
dose O
is O
not O
appropriate O
in O
this O
situation O
. O

5.3 O
Excessive O
Use O
of O
ANORO O
ELLIPTA O
and O
Use O
With O
Other O
Long-Acting O
Beta2-Agonists O
ANORO O
ELLIPTA O
should O
not O
be O
used O
more O
often O
than O
recommended O
, O
at O
higher O
doses O
than O
recommended O
, O
or O
in O
conjunction O
with O
other O
medicines O
containing O
LABA O
, O
as O
an O
overdose B-NonOSE_AE
may O
result O
. O

Clinically O
significant O
cardiovascular B-NonOSE_AE
effects I-NonOSE_AE
and O
fatalities O
have O
been O
reported O
in O
association O
with O
excessive O
use O
of O
inhaled O
sympathomimetic O
drugs O
. O

Patients O
using O
ANORO O
ELLIPTA O
should O
not O
use O
another O
medicine O
containing O
a O
LABA O
( O
e.g. O
, O
salmeterol O
, O
formoterol O
fumarate O
, O
arformoterol O
tartrate O
, O
indacaterol O
) O
for O
any O
reason O
. O

5.4 O
Drug O
Interactions O
With O
Strong O
Cytochrome O
P450 O
3A4 O
Inhibitors O
Caution O
should O
be O
exercised O
when O
considering O
the O
coadministration O
of O
ANORO O
ELLIPTA O
with O
long-term O
ketoconazole O
and O
other O
known O
strong O
cytochrome O
P450 O
3A4 O
( O
CYP3A4 O
) O
inhibitors O
( O
e.g. O
, O
ritonavir O
, O
clarithromycin O
, O
conivaptan O
, O
indinavir O
, O
itraconazole O
, O
lopinavir O
, O
nefazodone O
, O
nelfinavir O
, O
saquinavir O
, O
telithromycin O
, O
troleandomycin O
, O
voriconazole O
) O
because O
increased O
cardiovascular B-NonOSE_AE
adverse I-NonOSE_AE
effects I-NonOSE_AE
may O
occur O
[ O
see O
Drug O
Interactions O
( O
7.1 O
) O
, O
Clinical O
Pharmacology O
( O
12.3 O
) O
] O
. O

5.5 O
Paradoxical O
Bronchospasm O
As O
with O
other O
inhaled O
medicines O
, O
ANORO O
ELLIPTA O
can O
produce O
paradoxical B-OSE_Labeled_AE
bronchospasm I-OSE_Labeled_AE
, O
which O
may O
be O
life O
threatening O
. O

If O
paradoxical B-NonOSE_AE
bronchospasm I-NonOSE_AE
occurs O
following O
dosing O
with O
ANORO O
ELLIPTA O
, O
it O
should O
be O
treated O
immediately O
with O
an O
inhaled O
, O
short-acting O
bronchodilator O
; O
ANORO O
ELLIPTA O
should O
be O
discontinued O
immediately O
; O
and O
alternative O
therapy O
should O
be O
instituted O
. O

5.6 O
Hypersensitivity O
Reactions O
Hypersensitivity B-OSE_Labeled_AE
reactions O
may O
occur O
after O
administration O
of O
ANORO O
ELLIPTA O
. O

There O
have O
been O
reports O
of O
anaphylactic B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
in O
patients O
with O
severe O
milk B-Not_AE_Candidate
protein I-Not_AE_Candidate
allergy I-Not_AE_Candidate
after O
inhalation O
of O
other O
powder O
products O
containing O
lactose O
; O
therefore O
, O
patients O
with O
severe O
milk B-Not_AE_Candidate
protein I-Not_AE_Candidate
allergy I-Not_AE_Candidate
should O
not O
use O
ANORO O
ELLIPTA O
[ O
see O
Contraindications O
( O
4 O
) O
] O
. O

5.7 O
Cardiovascular O
Effects O
Vilanterol O
, O
like O
other O
beta2-agonists O
, O
can O
produce O
a O
clinically O
significant O
cardiovascular B-OSE_Labeled_AE
effect I-OSE_Labeled_AE
in O
some O
patients O
as O
measured O
by O
increases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
pulse I-OSE_Labeled_AE
rate I-OSE_Labeled_AE
, O
systolic O
or O
diastolic O
blood O
pressure O
, O
or O
symptoms O
[ O
see O
Clinical O
Pharmacology O
( O
12.2 O
) O
] O
. O

If O
such O
effects O
occur O
, O
ANORO O
ELLIPTA O
may O
need O
to O
be O
discontinued O
. O

In O
addition O
, O
beta-agonists O
have O
been O
reported O
to O
produce O
electrocardiographic B-OSE_Labeled_AE
changes I-OSE_Labeled_AE
, O
such O
as O
flattening B-OSE_Labeled_AE
of I-OSE_Labeled_AE
t I-OSE_Labeled_AE
he O
T O
wave I-OSE_Labeled_AE
, O
prolongation B-OSE_Labeled_AE
of I-OSE_Labeled_AE
the I-OSE_Labeled_AE
QTc I-OSE_Labeled_AE
interval I-OSE_Labeled_AE
, O
and O
ST B-OSE_Labeled_AE
segment I-OSE_Labeled_AE
depression I-OSE_Labeled_AE
, O
although O
the O
clinical O
significance O
of O
these O
findings O
is O
unknown O
. O

Therefore O
, O
ANORO O
ELLIPTA O
should O
be O
used O
with O
caution O
in O
patients O
with O
cardiovascular B-Not_AE_Candidate
disorders I-Not_AE_Candidate
, O
especially O
coronary B-Not_AE_Candidate
insufficiency I-Not_AE_Candidate
, O
cardiac B-Not_AE_Candidate
arrhythmias I-Not_AE_Candidate
, O
and O
hypertension B-Not_AE_Candidate
. O

5.8 O
Coexisting O
Conditions O
ANORO O
ELLIPTA O
, O
like O
all O
medicines O
containing O
sympathomimetic O
amines O
, O
should O
be O
used O
with O
caution O
in O
patients O
with O
convulsive B-Not_AE_Candidate
disorders I-Not_AE_Candidate
or O
thyrotoxicosis B-Not_AE_Candidate
and O
in O
those O
who O
are O
unusually O
responsive O
to O
sympathomimetic O
amines O
. O

Doses O
of O
the O
related O
beta2-adrenoceptor O
agonist O
albuterol O
, O
when O
administered O
intravenously O
, O
have O
been O
reported O
to O
aggravate O
preexisting O
diabetes B-NonOSE_AE
mellitus I-NonOSE_AE
and O
ketoacidosis B-NonOSE_AE
. O

5.9 O
Worsening O
of O
Narrow B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Angle I-OSE_Labeled_AE
Glaucoma I-OSE_Labeled_AE
ANORO O
ELLIPTA O
should O
be O
used O
with O
caution O
in O
patients O
with O
narrow B-Not_AE_Candidate
- I-Not_AE_Candidate
angle I-Not_AE_Candidate
glaucoma I-Not_AE_Candidate
. O

Prescribers O
and O
patients O
should O
be O
alert O
for O
signs O
and O
symptoms O
of O
acute B-NonOSE_AE
narrow I-NonOSE_AE
- I-NonOSE_AE
angle I-NonOSE_AE
glaucoma I-NonOSE_AE
( O
e.g. O
, O
eye B-NonOSE_AE
pain I-NonOSE_AE
or O
discomfort B-NonOSE_AE
, O
blurred B-NonOSE_AE
vision I-NonOSE_AE
, O
visual B-NonOSE_AE
halos I-NonOSE_AE
or O
colored O
images O
in O
association O
with O
red B-NonOSE_AE
eyes I-NonOSE_AE
from O
conjunctival B-NonOSE_AE
congestion I-NonOSE_AE
and O
corneal B-NonOSE_AE
edema I-NonOSE_AE
) O
. O

Instruct O
patients O
to O
consult O
a O
physician O
immediately O
if O
any O
of O
these O
signs O
or O
symptoms O
develops O
. O

5.10 O
Worsening O
of O
Urinary B-OSE_Labeled_AE
Retention I-OSE_Labeled_AE
ANORO O
ELLIPTA O
should O
be O
used O
with O
caution O
in O
patients O
with O
urinary B-Not_AE_Candidate
retention I-Not_AE_Candidate
. O

Prescribers O
and O
patients O
should O
be O
alert O
for O
signs O
and O
symptoms O
of O
urinary B-NonOSE_AE
retention I-NonOSE_AE
( O
e.g. O
, O
difficulty B-NonOSE_AE
passing I-NonOSE_AE
urine I-NonOSE_AE
, O
painful B-NonOSE_AE
urination I-NonOSE_AE
) O
, O
especially O
in O
patients O
with O
prostatic B-Not_AE_Candidate
hyperplasia I-Not_AE_Candidate
or O
bladder B-Not_AE_Candidate
- I-Not_AE_Candidate
neck I-Not_AE_Candidate
obstruction I-Not_AE_Candidate
. O

Instruct O
patients O
to O
consult O
a O
physician O
immediately O
if O
any O
of O
these O
signs O
or O
symptoms O
develops O
. O

5.11 O
Hypokalemia O
and O
Hyperglycemia O
Beta-adrenergic O
agonist O
medicines O
may O
produce O
significant O
hypokalemia B-OSE_Labeled_AE
in O
some O
patients O
, O
possibly O
through O
intracellular O
shunting O
, O
which O
has O
the O
potential O
to O
produce O
adverse O
cardiovascular B-NonOSE_AE
effects I-NonOSE_AE
. O

The O
decrease B-OSE_Labeled_AE
in I-OSE_Labeled_AE
serum I-OSE_Labeled_AE
potassium I-OSE_Labeled_AE
is O
usually O
transient O
, O
not O
requiring O
supplementation O
. O

Beta-agonist O
medicines O
may O
produce O
transient O
hyperglycemia B-OSE_Labeled_AE
in O
some O
patients O
. O

In O
4 O
clinical O
trials O
of O
6-month O
duration O
evaluating O
ANORO O
ELLIPTA O
in O
subjects O
with O
COPD B-Not_AE_Candidate
, O
there O
was O
no O
evidence O
of O
a O
treatment O
effect O
on O
serum O
glucose O
or O
potassium O
. O

